INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)-Reference-Cited by-同舟云学术

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)

Published:2022-07 Issue:3 Volume:12 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Hill Nicholas S.¹^ORCID,Feldman Jeremy P.²,Sahay Sandeep³^ORCID,Benza Raymond L.⁴,Preston Ioana R.¹,Badesch David⁵,Frantz Robert P.⁶,Patel Savan⁷,Galloway Ashley⁷,Bull Todd M.⁵,

Affiliation:

1. Tufts Medical Center Boston Massachusetts USA

2. Arizona Pulmonary Specialists, Ltd Phoenix Arizona USA

3. Weill Cornell Medicine, Houston Methodist Lung Center, Houston Methodist Houston Texas USA

4. The Ohio State University Columbus Ohio USA

5. Anschutz Medical Campus, University of Colorado Denver Aurora Colorado USA

6. Mayo Clinic Rochester Minnesota USA

7. Liquidia Technologies Morrisville North Carolina USA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12119

Reference37 articles.

1. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities

2. Prostacyclin for pulmonary arterial hypertension;Barnes H;Cochrane Database Syst Rev,2019

3. Prostacyclin therapies for the treatment of pulmonary arterial hypertension

4. Remodulin (treprostinil injection) [package insert]. Research Triangle Park North Carolina: United Therapeutics Corp.; 2018.

5. Veletri (epoprostenol) [package insert]. South San Francisco California: Actelion Pharmaceuticals US Inc.; 2018.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Pulmonary Arterial Hypertension;Seminars in Respiratory and Critical Care Medicine;2023-06-27

2. Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies;BMC Pediatrics;2023-01-25